MedCity

MedCity News and Quantum Health Launch New Healthcare Benefit Consultant Sentiment Index: Predicts Point Solution Consolidation and Employer Need for Integration

Retrieved on: 
Tuesday, September 12, 2023

MedCity News, the leading online news source for the business of innovation in healthcare, and Quantum Health , the industry-leading healthcare navigation and care coordination company, announced today the results of their inaugural Benefit Consultant Sentiment Index (The Index) : Benefit Consultants’ Perspective on Shifting Employer Healthcare Landscape.

Key Points: 
  • MedCity News, the leading online news source for the business of innovation in healthcare, and Quantum Health , the industry-leading healthcare navigation and care coordination company, announced today the results of their inaugural Benefit Consultant Sentiment Index (The Index) : Benefit Consultants’ Perspective on Shifting Employer Healthcare Landscape.
  • Topics included cost management and health equity strategies, the increasing role of artificial intelligence (AI) in optimizing the patient experience and perspectives on trends in healthcare navigation.
  • Consultants also envision consolidation and integration as the future for healthcare navigation.
  • See The Index full survey revealing consultants’ unique perspectives on the shifting healthcare landscape, employers’ priorities and employee benefits expectations.

CMS Assigns New Technology Payment Classification for Optellum's Lung Cancer Prediction Score

Retrieved on: 
Tuesday, June 28, 2022

HOUSTON and OXFORD, United Kingdom, June 28, 2022  /PRNewswire/ -- Optellum announced that the Centers for Medicare & Medicaid Services (CMS) has established a national payment rate for Optellum's Lung Cancer Prediction technology under the New Technology Ambulatory Payment Classification. This development will facilitate the process of health insurance claims for individuals enrolled in Medicare and other health insurance programs, enabling more patients to access innovative, potentially life-saving early lung cancer diagnostic technology.

Key Points: 
  • HOUSTON and OXFORD, United Kingdom, June 28, 2022 /PRNewswire/ -- Optellum announced that the Centers for Medicare & Medicaid Services (CMS) has established a national payment rate for Optellum's Lung Cancer Prediction technology under the New Technology Ambulatory Payment Classification.
  • "This is another step in Optellum's progress towards becoming the standard of care for early lung cancer diagnosis.
  • "This new payment assignment is an important step towards incentivizing providers to make the technology more widely available."
  • He has extensive experience in the application and translation of imaging research for evaluating lung nodules and lung cancer.

Mursla Gains Mentorship Support From Roche Diagnostics Ltd for Pilot Study in Cirrhotic and Liver Cancer Patients

Retrieved on: 
Tuesday, March 29, 2022

Mursla, a novel multi-omics exosome characterisation company, is pleased to announce that it has secured mentorship support from Roche Diagnostics Ltd for a new liquid biopsy prospective pilot study for liver cancer surveillance through MedCitys Collaborate to Innovate: London Diagnostics programme.

Key Points: 
  • Mursla, a novel multi-omics exosome characterisation company, is pleased to announce that it has secured mentorship support from Roche Diagnostics Ltd for a new liquid biopsy prospective pilot study for liver cancer surveillance through MedCitys Collaborate to Innovate: London Diagnostics programme.
  • Liver cancer is the third most common cause of premature cancer death worldwide and its incidence has increased significantly over other forms of cancer in the last three decades.
  • To enable the pilot study, Mursla will leverage its proprietary multi-omics exosome characterisation platform technology for the discovery and profiling of exosome phenotypes, ExoPheno.
  • Gerard Harkin, Head of Innovation UK & Ireland, Roche Diagnostics Ltd commented: We are delighted to support the MedCity programme that encourages innovations in diagnostics and to provide in-kind mentorship to Mursla.

Mahana Therapeutics Selected for Prestigious Digitalhealth.London Accelerator Program

Retrieved on: 
Tuesday, January 18, 2022

Mahana Therapeutics , a leading developer of prescription digital therapeutics designed to empower people living with chronic health conditions, today announced that Mahana has been selected for the DigitalHealth.Londons Accelerator programme .

Key Points: 
  • Mahana Therapeutics , a leading developer of prescription digital therapeutics designed to empower people living with chronic health conditions, today announced that Mahana has been selected for the DigitalHealth.Londons Accelerator programme .
  • The program will help Mahana Therapeutics better engage with the NHS to accelerate adoption of Mahana IBS in clinical practice.
  • We are excited to join this prestigious program to accelerate adoption of and experience with Mahana IBS within the NHS.
  • Mahana Therapeutics is a leading developer of effective prescription digital therapeutics that are designed to empower patients with chronic conditions to live fuller lives.

Sixfold Bioscience Completes $10.5M USD (£7.8M GBP) Seed Financing

Retrieved on: 
Thursday, December 2, 2021

Sixfold Bioscience (Sixfold), a company harnessing computation and advanced chemistry to design RNA therapeutic delivery systems, today announced it has raised a total of $10.5 million USD (7.8 million GBP) in its seed funding round.

Key Points: 
  • Sixfold Bioscience (Sixfold), a company harnessing computation and advanced chemistry to design RNA therapeutic delivery systems, today announced it has raised a total of $10.5 million USD (7.8 million GBP) in its seed funding round.
  • This most recent second close of the seed financing raised $2.2 million USD, bringing the total dilutive and non-dilutive capital raised to $10.5 million USD.
  • Investors in the seed round included Cantos Ventures, Y Combinator, Lombard Street Ventures and Pi Campus, as well as select Angel investors.
  • Dr George Foot, Founder & co-CEO, Sixfold Bioscience, said: Were grateful for the continued support from our investors, as well as welcoming new investors to Sixfold in the second close.

Spex Capital and MedCity joint investment call goes live to source and fund breakthrough health-tech ventures

Retrieved on: 
Monday, September 20, 2021

LONDON, Sept. 20, 2021 /PRNewswire/ -- Investment firm Spex Capital and London's life sciences cluster organisation MedCity have opened their first joint call as part of their exclusive partnership to identify and fund the next generation of digital health and medtech innovators. Applications are invited from early-stage health-tech ventures with solutions to problems faced by healthcare systems globally. Interested companies can complete their applications for seed or series A rounds by October 27th, 2021.

Key Points: 
  • LONDON, Sept. 20, 2021 /PRNewswire/ -- Investment firm Spex Capital and London's life sciences cluster organisation MedCity have opened their first joint call as part of their exclusive partnership to identify and fund the next generation of digital health and medtech innovators.
  • Applications are invited from early-stage health-tech ventures with solutions to problems faced by healthcare systems globally.
  • MedCity will use its extensive networks and expertise to attract and assess applications from companies developing breakthrough digital health tech and medtech.
  • Founded in 2021 by serial health tech entrepreneur Claudio D'Angelo, London-based Spex Capital has a portfolio of six high-growth heath-tech companies.

Spex Capital and MedCity joint investment call goes live to source and fund breakthrough health-tech ventures

Retrieved on: 
Wednesday, September 15, 2021

Applications are invited from early-stage health-tech ventures with solutions to problems faced by healthcare systems globally.

Key Points: 
  • Applications are invited from early-stage health-tech ventures with solutions to problems faced by healthcare systems globally.
  • The call comes against the backdrop of the pandemic, which has accelerated the use of digital health solutions and diagnostics devices.
  • MedCity will use its extensive networks and expertise to attract and assess applications from companies developing breakthrough digital health tech and medtech.
  • Founded in 2021 by serial health tech entrepreneur Claudio D'Angelo, London-based Spex Capital has a portfolio of six high-growth heath-tech companies.

Doctors Hospital Takes Action to Preserve Fair Competition After the Cayman Government Grants a Series of Financial Concessions

Retrieved on: 
Friday, March 19, 2021

GEORGE TOWN, Cayman Islands, March 19, 2021 /PRNewswire/ -- Doctors Hospital ("DH") in Grand Cayman, Cayman Islands, announced they are seeking a judicial review of the vast unilateral concessions made by the government to Health City and Aster Cayman MedCity.

Key Points: 
  • GEORGE TOWN, Cayman Islands, March 19, 2021 /PRNewswire/ -- Doctors Hospital ("DH") in Grand Cayman, Cayman Islands, announced they are seeking a judicial review of the vast unilateral concessions made by the government to Health City and Aster Cayman MedCity.
  • According to DH, these concessions unfairly distort competition between healthcare providers on the Cayman Islands, and could ultimately compromise the quality of healthcare available.
  • DH challenges the fairness of the ongoing grant of financial concessions to Narayana Hrudayalaya Private Limited ("NHP") by the Government of the Cayman Islands ("CIG") for the current Health City development.
  • Also, granting vast financial concessions to DM Healthcare ("DM") for the Aster Cayman MedCity development, and the proposed financial concessions to NHP for the proposed development at Camana Bay is concerning.

Doctors Hospital Takes Action to Preserve Fair Competition After the Cayman Government Grants a Series of Financial Concessions

Retrieved on: 
Friday, March 19, 2021

GEORGE TOWN, Cayman Islands, March 19, 2021 /PRNewswire/ -- Doctors Hospital ("DH") in Grand Cayman, Cayman Islands, announced they are seeking a judicial review of the vast unilateral concessions made by the government to Health City and Aster Cayman MedCity.

Key Points: 
  • GEORGE TOWN, Cayman Islands, March 19, 2021 /PRNewswire/ -- Doctors Hospital ("DH") in Grand Cayman, Cayman Islands, announced they are seeking a judicial review of the vast unilateral concessions made by the government to Health City and Aster Cayman MedCity.
  • According to DH, these concessions unfairly distort competition between healthcare providers on the Cayman Islands, and could ultimately compromise the quality of healthcare available.
  • DH challenges the fairness of the ongoing grant of financial concessions to Narayana Hrudayalaya Private Limited ("NHP") by the Government of the Cayman Islands ("CIG") for the current Health City development.
  • Also, granting vast financial concessions to DM Healthcare ("DM") for the Aster Cayman MedCity development, and the proposed financial concessions to NHP for the proposed development at Camana Bay is concerning.

RYSE Extends Partnership With DigitalHealth.London and MedCity to Invest in Early Stage Digital Health Companies

Retrieved on: 
Thursday, June 27, 2019

The second RYSE Digital Health Call opens today and is inviting applications from early stage companies that are seeking funding to grow their businesses.

Key Points: 
  • The second RYSE Digital Health Call opens today and is inviting applications from early stage companies that are seeking funding to grow their businesses.
  • The parties are working exclusively together on this Call where DH.L and MedCity will again assist with the appraisal of promising UK digital health companies.
  • The call resulted in nearly 300 applications for investment from early stage digital health companies in the UK.
  • It's great to continue this partnership with RYSE, who are ready to invest a substantial pot of funding into the digital health companies of tomorrow."